N-Methyl Leukotriene C4

Synonyms: N-Methyl-LTC4
N-Methyl Leukotriene C4 (N-Methyl-LTC4) 是一种不可代谢的 LTC4 模拟物,也是选择性半胱氨酰白三烯受体 2 (CysLT2) 受体激活剂,对小鼠 CysLT2 的 EC50 为 46.1 nM,对人 CysLT2 的 EC50 为 122.3 nM,对 CysLT1 效力较低;它可激活人和小鼠 CysLT2 受体,触发钙信号传导、β-抑制蛋白-2 与磷酸化受体的结合、血管渗漏、低血压、心率加快、豚鼠回肠和气管收缩、轻度支气管收缩以及与外周血管收缩相关的高血压,可用于哮喘、鼻炎、鼻窦炎、脑部炎症与水肿、肺动脉高压和心血管疾病的研究。
产品编号: MS-J26769 纯度: 98.1% CAS No.: 131391-65-6 分子式: C31H49N3O9S 分子量: 639.80
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
25μg (390.75μM * 100μL in Ethanol)
询价
3-5 天

产品描述

N-Methyl Leukotriene C4 (N-Methyl-LTC4) 是一种不可代谢的 LTC4 模拟物,也是选择性半胱氨酰白三烯受体 2 (CysLT2) 受体激活剂,对小鼠 CysLT2 的 EC50 为 46.1 nM,对人 CysLT2 的 EC50 为 122.3 nM,对 CysLT1 效力较低;它可激活人和小鼠 CysLT2 受体,触发钙信号传导、β-抑制蛋白-2 与磷酸化受体的结合、血管渗漏、低血压、心率加快、豚鼠回肠和气管收缩、轻度支气管收缩以及与外周血管收缩相关的高血压,可用于哮喘、鼻炎、鼻窦炎、脑部炎症与水肿、肺动脉高压和心血管疾病的研究。

生物实验数据

生物活性 N-Methyl Leukotriene C4 (N-Methyl-LTC4) is a non-metabolizable LTC4 mimetic and a selective cysteinyl leukotriene receptor 2 (CysLT2) receptor activator with an EC50 of 46.1 nM for mouse CysLT2 and an EC50 of 122.3 nM for human CysLT2, while showing lower potency at CysLT1; it activates human and mouse CysLT2 receptors, triggering calcium signaling, β-arrestin-2 binding to phosphorylated receptors, vascular leakage, hypotension, increased heart rate, guinea pig ileum and trachea contraction, mild bronchoconstriction, and hypertension associated with peripheral vasoconstriction, and can be used for research on asthma, rhinitis, sinusitis, brain inflammation and edema, pulmonary arterial hypertension, and cardiovascular diseases.
IC50 & Target

CysLT2

122.3 nM (IC50, Human)

CysLT2

46.1 nM (IC50, Mouse)

CysLT1

>2000 nM (IC50, Human)

CysLT1

>3000 nM (IC50, Mouse)

体外研究
(In Vitro)

N-Methyl Leukotriene C4 (3 μM; 1 h, 30 s) 可作为 HEK 293 细胞中人类 CysLT2 受体的完全强效激动剂,其 EC50 为 122.3 nM,达到 LTC4 最大效能的 98%。
N-Methyl Leukotriene C4 (serial dilutions, 1.5 μM; 1 h, 30 s) 是 HEK 293 细胞中小鼠 CysLT2 受体的完全强效激动剂,其 EC50 为 46.1 nM,达到 LTC4 最大效能的 89%。
N-Methyl Leukotriene C4 (10-40 μM; 1 h, 30 s) 是人源 CysLT1 受体的极弱部分激动剂,作用于 HEK 293 细胞,其 EC50≥2000 nM,最大效能为 LTD4 的 60%。
N-Methyl Leukotriene C4 可作为人 CysLT2 受体介导的 C2C12 肌成纤维细胞中 β-arrestin-2 结合的完全强效激动剂,其 EC50 为 8.7 nM,最大效力可达 LTC4 的 90%。
N-Methyl Leukotriene C4 (0.4 μg/mL; up to 30 min) 不会被豚鼠肺上清匀浆代谢,表明其对 γ-谷氨酰转肽酶介导的降解具有稳定性。
N-Methyl Leukotriene C4 (单次推注给药,10 μg) 在离体灌流豚鼠肺中不会代谢为 LTD4,且其诱导的灌注压升高作用无法被FPL55712 (MS-R71406) 拮抗。
N-Methyl Leukotriene C4 可诱导豚鼠回肠产生浓度依赖性收缩,其 pD2 值为 7.7。
N-Methyl Leukotriene C4 可诱导豚鼠气管产生浓度依赖性收缩,其 pD2 值为 8.1。

体内研究
(In Vivo)

N-Methyl Leukotriene C4 (5 ng;皮内注射;单次给药) 是一种强效的、CysLT2 受体选择性激动剂,可使内皮细胞过表达人 CysLT2 受体的转基因小鼠血管通透性提升 22 倍,而对 CysLT2 受体敲除小鼠无显著作用。
N-Methyl Leukotriene C4 (10-1000 ng/kg bw;静脉注射;单次推注) 在插管美洲牛蛙体内产生的降压作用比天然肽白三烯更强、持续时间更长,且其心血管效应会被剂量为 100 ng/kg bw 及以上的高剂量 Ablukast (Ro 23-3544) (MS-I49910) 拮抗。
N-Methyl Leukotriene C4 (15-40 μg/kg;静脉注射) 在麻醉豚鼠中可作为一种弱效、呈剂量依赖性的静脉用支气管收缩剂,其效力比 LTC4 低 25 倍,且其支气管收缩作用可被 FPL55712 显著抑制。
N-Methyl Leukotriene C4 (20 μg/kg;静脉注射) 可在麻醉豚鼠中诱发显著且持久的升压效应,该效应不受 LTD4/LTE4 拮抗剂、脂氧合酶抑制剂或 α-肾上腺素受体拮抗剂的显著影响。

Animal Model: transgenic mice overexpressing human CysLT2 receptor in vascular endothelial cells (TG-EC); CysLT2 receptor knockout (KO) mice
Dosage: 5 ng
Administration: i.d.; single dose
Result: Elicited a 22-fold increase in vascular leakage compared with vehicle control in TG-EC mice, with an average absorbance of 0.26 versus 0.012 for vehicle.
Did not produce a statistically significant increase in vascular leakage in CysLT2 receptor KO mice, with an average absorbance of 0.034 versus 0.063 for vehicle.
Animal Model: American bullfrog (both sexes, 368.06 g)
Dosage: 10 ng/kg bw; 30 ng/kg bw; 100 ng/kg bw; 300 ng/kg bw; 1000 ng/kg bw
Administration: i.v.; single bolus
Result: Exhibited equivalent hypotensive (ΔMAP) potency to LTC4, LTD4, and LTE4 at 10 and 30 ng/kg bw.
Produced the most potent hypotensive effect at 100, 300, and 1000 ng/kg bw, with significantly greater ΔMAP reduction than LTC4, LTD4, and LTE4.
Induced significantly greater HR responses than LTD4 and LTE4 at doses of 100 ng/kg bw and higher.
Caused significantly longer duration of cardiovascular effects than LTC4, LTD4, and LTE4 at doses as low as 30 ng/kg bw.
Showed significantly reduced MAP and HR responses when co-administered with high-dose Ro 23-3544 at doses of 100 ng/kg bw and higher.
Animal Model: Dunkin-Hartley (male, 350-450 g, anaesthetised, artificially ventilated, indomethacin pretreatment)
Dosage: 15 μg/kg; 20 μg/kg; 40 μg/kg
Administration: i.v.
Result: Produced a dose-dependent increase in total pulmonary resistance (TPR).
Increased TPR by ~2% at 15 μg/kg, ~15% at 20 μg/kg, and ~40% at 40 μg/kg.
Was approximately 25 times less potent than LTC4 as an intravenous bronchoconstrictor.
Induced a TPR increase of 37% and a mean arterial blood pressure (MAP) increase of 51 mmHg at 20 μg/kg i.v.
Reduced the TPR increase by 73% (to 10%) when pretreated with FPL55712 (0.5 mg/kg i.v.), but did not significantly affect the MAP increase.
Animal Model: Dunkin-Hartley (male, 350-450 g, anaesthetised, artificially ventilated, propranolol pretreatment)
Dosage: 10 μg/mL; 20 μg/mL; 30 μg/mL
Administration: aerosolised; 20 sec
Result: Produced a dose-dependent increase in total pulmonary resistance (TPR).
Increased TPR by ~28% at 10 μg/mL, ~58% at 20 μg/mL, and ~88% at 30 μg/mL.
Was approximately 20 times less potent than LTC4 as an inhaled bronchoconstrictor.
Reduced the TPR response by an average of 91% when pretreated with FPL55712 (0.5 mg/kg i.v.).
Reduced the TPR response by 71% when treated with aerosolised LY170680 (0.5 mg/mL for 20 sec).
Caused no change in mean arterial blood pressure (MAP).
Animal Model: Dunkin-Hartley (male, 350-450 g, anaesthetised, artificially ventilated, indomethacin and propranolol pretreatment)
Dosage: 20 μg/kg
Administration: i.v.
Result: Induced a mean arterial blood pressure (MAP) increase of 51 mmHg at 20 μg/kg i.v.
Showed no significant change in hypertensive effect when pretreated with FPL55712 (0.5 mg/kg i.v.), AA861 (5 mg/kg i.v.), or phenoxybenzamine (1 mg/kg i.v.).
性状 液体

化学信息

分子量 639.80
分子式 C31H49N3O9S
CAS No. 131391-65-6
别名 N-Methyl-LTC4

储存&溶解度

溶解度信息
DMF: 25 mg/mL (39.07 mM), Sonication is recommended.
DMSO: 25 mg/mL (39.07 mM), Sonication is recommended.
PBS (pH 7.2): < 1 mg/mL (insoluble), Sonication is recommended.
Ethanol:H2O (95:5): 1 mg/mL (1.56 mM), Sonication is recommended.
Ethanol: < 1 mg/mL (insoluble), Sonication is recommended.
储存方式

-80°C

运输条件 Shipping with dry ice.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础